Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Ageusia

ClinicalTrials.gov lists 16 trials for Ageusia or a narrower condition beneath it.

MeSH D000370 Nervous System Diseases C10 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 1 Phase 3 Phase 3 1 Not applicable Not applicable 8 Observational Observational 5 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 1 Phase 3 Phase 3 1 Not applicable Not applicable 8 Observational Observational 5

Trials per phase

16 of the 16 trials are tagged with Ageusia itself; the rest are tagged with a narrower condition beneath it.

Get the Ageusia report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Ageusia trials start? (6)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1/2
  • Phase 2
  • Phase 3
  • Not applicable
  • Observational

Top of scale: 6

2012: 1 trials (Not applicable 1) 2017: 1 trials (Observational 1) 2020: 6 trials (Observational 4, Not applicable 1, Phase 3 1) 2021: 4 trials (Not applicable 2, Phase 2 1, Phase 1/2 1) 2022: 3 trials (Not applicable 3) 2024: 1 trials (Not applicable 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2024 1
2022 3
2021 4
2020 6
2017 1
2012 1

No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: none of the 16 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Ageusia trials in? (5)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1/2 1
Phase 2 1
Phase 3 1
Not applicable 8
Observational 5

How many Ageusia trials are recruiting? (3)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Completed 12
Withdrawn 1
Unknown status 3

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Ageusia trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Hospital General de Mexico 1
Singapore Institute of Food and Biotechnology Innovation 1

Which drugs are being tested for Ageusia? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cerebrolysin 1
Talactoferrin 1
Sucrose 1

Interventions as named in the registry (2)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Reporting of anosmia, ageusia and other clinical symptoms 1
theophylline SR 1

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which publications cover Ageusia? (19)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages